Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Pharmacyclics Inc

+ Add to Watchlist

PY2:GR

235.706 EUR 3.097 1.30%

As of 14:09:37 ET on 04/17/2015.

Snapshot for Pharmacyclics Inc (PY2)

Open: 236.891 Day's Range: 235.491 - 241.460 Volume: 7
Previous Close: 238.803 52wk Range: 61.902 - 246.649 1-Yr Rtn: +250.63%

Stock Chart for PY2

No chart data available.
  • PY2:GR 238.670
  • 1D
  • 1M
  • 1Y
238.803
Interactive PY2 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PY2

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 176.9272
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) 1.4360
Est. PEG Ratio 4.9283
Market Cap (M EUR) 17,917.64
Shares Outstanding (M) 76.02
30 Day Average Volume 150
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PY2

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for PY2

Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs.

Robert W Duggan "Bob"Chairman/CEOManmeet SoniCFO/Treasurer
Mahkam Zanganeh "Maky"Chief Operating OfficerShawn Cline TomaselloChief Commercial Officer
More Company Profile & Key Executives for PY2

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil